T1	p 104 115	hypertrophy
T2	p 242 243	)
T3	p 283 308	ventricular hypertrophy (
T4	p 330 382	continuous ambulatory peritoneal dialysis ( CAPD ) .
T5	p 409 441	24 CAPD patients with LVH [ left
T6	p 480 494	g/m2 for women
T7	p 499 503	LVMi
T8	p 510 524	g/m2 for men ]
T9	p 589 600	valsartan (
T10	p 603 607	= 14
T11	p 627 628	=
T12	p 1276 1285	diastolic
T13	p 1319 1337	treated with ARB .
T14	p 1385 1403	treated with ARB (
T15	p 1581 1582	.
T16	p 1586 1608	CAPD patients with LVH
T17	i 18 49	angiotensin receptor antagonist
T18	i 52 61	Valsartan
T19	i 194 243	selective angiotensin II receptor blocker ( ARB )
T20	i 341 362	ambulatory peritoneal
T21	i 467 473	LVMi )
T22	i 585 598	ARB valsartan
T23	i 613 624	a placebo (
T24	i 840 853	reflections [
T25	i 910 935	) application tonometry ]
T26	i 948 966	echocardiography .
T27	i 1008 1039	BP ( mercury sphygmomanometer )
T28	i 1332 1337	ARB .
T29	i 1398 1401	ARB
T30	i 1461 1470	placebo (
T31	i 1611 1614	ARB
T32	o 73 83	regression
T33	o 144 165	of arterial stiffness
T34	o 442 458	ventricular mass
T35	o 640 668	target blood pressure ( BP )
T36	o 798 911	large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI )
T37	o 994 1020	body weight , BP ( mercury
T38	o 1038 1171	) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .
T39	o 1263 1288	Systolic and diastolic BP
T40	o 1570 1580	PWV and AI
T41	o 1663 1684	arterial hemodynamics